OKYO Pharma logo

OKYO - OKYO Pharma News Story

10.13p -0.1  -1.2%

Last Trade - 18/09/20

Sector
Healthcare
Size
Small Cap
Market Cap £64.4m
Enterprise Value £64.3m
Revenue £n/a
Position in Universe 1091st / 1807

OKYO Pharma Limited - Expected Admission Date for Consideration Shares

Thu 1st November, 2018 7:00am
RNS Number : 9455F
OKYO Pharma Limited
01 November 2018
 

 

1 November 2018

 

 

OKYO Pharma Limited
(Incorporated and registered in Guernsey with registered number 65220) 

 

Expected Admission Date for Consideration Shares

 

OKYO Pharma Limited (LSE:OKYO) (the "Company") today announces that in connection with its announcement on 24 October 2018 (the "24 October Announcement"), regarding its agreement to allot 512,866 ordinary shares of no par value in the capital of the Company (the "Consideration Shares") to Dr. Alan Kopin and Dr. Benjamin Harwood in lieu of a cash payment pursuant to the terms of the Amended Collaboration Agreement (as defined in the 24 October Announcement), that such Consideration Shares are expected to be admitted to listing on the standard segment of the Official List maintained by the Financial Conduct Authority under Chapter 14 of the Listing Rules and to trading on the main market for listed securities of London Stock Exchange plc on 5 November 2018.

 

End

 

Enquiries:

 

OKYO Pharma Limited

Willy Simon

 

+44 (0)20 7382 8300

Stockdale Securities Limited (Broker)

Andy Crossley

Antonio Bossi

David Coaten

+44 (0)20 7601 6100

 

 

For further information, please visit the Company's website at www.okyopharma.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCDMMFGNMVGRZM
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.